Type two Diabetes Mellitus (DM) Nutritional, Metabolic, Endocrine Diabetes mellitus
Conditions
Interventions
The patients were randomly allocated by a computer algorithm to one of two groups for treatment with 4 mg perindopril per os or placebo for six months, in an open-label, parallel-group, randomised des
Sponsors
Heraklion University Hospital (Greece)
Eligibility
Inclusion criteria
Inclusion criteria: The study population was recruited from the Cardiology Outpatients? Department. All participants: 1. Had type two DM (World Health Organisation criteria) 2. Were diagnosed at an age over 30 years 3. Had DM controlled by diet or blood glucose-lowering agents for at least six months 4. Were normotensive (Blood Pressure [BP] less than 130/85 mmHg) 5. Had no indications of other organic heart disease
Exclusion criteria
Exclusion criteria: 1. Heavy smokers 2. Pregnant or lactating women 3. Type one DM or secondary diabetes 4. Previous or ongoing treatment with ACE-i, angiotensin receptor blockers, antioxidant or immunosuppressive agents 5. Systolic BP less than 100 mmHg or diastolic BP less than 50 mmHg 6. Poor glycaemic control 7. Hyperuricaemia 8. Previous history or medication for hypertension, cerebrovascular, liver or renal disease 9. Serum potassium more than 5 mEq/L 10. Albumin excretion rate more than 200 µg/min 11. History of drug or alcohol abuse 12. Any chronic inflammatory or other infectious disease during the last six months 13. Uncontrolled hypothyroidism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of total peroxides, interleukin-6 and a tumour necrosis factor-alpha were performed before and six months after the initiation of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of cardiac adrenergic innervation before and after perindopril treatment. | — |
Countries
Greece
Outcome results
None listed